Early Outpatient Treatment Of Symptomatic COVID-19 With Fluvoxamine: A New Potential Therapy!

Whiteboard Doctor | November 20, 2020

In this video we will discuss a new study that was published in the Journal of the American Medical Association that looked at using Fluvoxamine, a Selective Serotonin Reuptake Inhibitor (SSRI) that also has been shown to inhibit cytokine production, in early outpatient COVID-19.

Be the First to Know

Sign up to get updates when we add new off-label treatments, articles, videos, and clinical trials!